


Cohort 1: Either of the following taxanes administered every 3 weeks:
Docetaxel 75-100 mg/m^2 IV
Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV
Cohort 2: Any of the following anthracycline-based combination chemotherapies, for subjects previously untreated with anthracyclines, every 3 weeks:
FEC: 5-fluorouracil 500 mg/m^2 IV, epirubicin 90-100 mg/m^2 IV, and cyclophosphamide 500 mg/m^2 IV on Day 1
FAC: 5-fluorouracil 500 mg/m^2 IV, doxorubicin 50 mg/m^2 IV, and cyclophosphamide 500 mg/m^2 IV on Day 1
AC: Doxorubicin 50-60 mg/m^2 IV and cyclophosphamide 500-600 mg/m^2 IV on Day 1
EC: Epirubicin 90-100 mg/m^2 IV and cyclophosphamide 500-600 mg/m^2 IV on Day 1
Cohort 3: Capecitabine 1000 mg/m^2 oral twice daily on Days 1-14 of each 3-week cycle

FIG. 1



Capecitabine: PFS by Investigator
PL (n=206)
BV (n=409)
INV
Median, mo 5.7 8.6
HR (95% CI) 0.69 (0.56-0.84)
p-value p=0.0002
IRC
Median, mo 6.2 9.7
HR (95% CI) 0.68 (0.54-0.86)
p-value p=0.0011
BV
PL
PFS
1.0
0.8
0.6
0.4
0.2
0.0
0
4
8
12
16
20
24
28
Time (mo)

FIG. 2



Taxane/Anthra: PFS by Investigator
PL (n=207)
BV (n=415)
INV
Median, mo 8.0 9.2
HR (95% CI) 0.64 (0.52-0.80)
p-value p<0.0001
IRC
Median, mo 8.3 10.7
HR (95% CI) 0.77 (0.60-0.99)
p-value p=0.040
BV
PL
PFS
1.0
0.8
0.6
0.4
0.2
0.0
0
4
8
12
16
20
24
28
Time (mo)

FIG. 3



Subgroup Analyses of PFS, Cape and T/Anthra Cohorts
Cape
T/Anthra
Baseline Factor
Total n
Hazard Ratio
+ BV Better
+ PL Better
Total n
Hazard Ratio
+ BV Better
+ PL Better
All Patients 615 0.67 622 0.66
Disease-free Interval (mo)
≤12 154 0.81 239 0.62
>12 461 0.63 383 0.69
Number of Metastatic Sites
<3 345 0.63 341 0.65
≥3 270 0.74 281 0.64
Prior Adjuvant Chemotherapy
Yes 444 0.64 283 0.67
No 171 0.74 339 0.64
0.2
0.5
1
2
0.2
0.5
1
2

FIG. 4



Objective Response Rate
Cape
p=0.0097
T/Anthra
p=0.0054
60
50
40
30
20
10
0
%
23.6
35.4
37.9
51.3
CR
PR
PL
BV
PL
BV
Measurable* Disease, %
78
80
86
83
*Includes only patients with measurable disease at baseline.

FIG. 5



Subgroup Analyses of PFS T/Anthra Cohorts
T/Anthra
Baseline Factor
Total n
Hazard Ratio
+ BV Better
+ PL Better
All Patients
622
0.66
Taxane
Docetaxel
181
0.78
Abraxane
124
0.65
Anthracycline-based Chemotherapy
Doxorubicin-based
236
0.63
Epirubicin-based
74
0.46
0.2
0.5
1
2
5

FIG. 6